Biotech entity
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention BioFlorida, the most common co-covered peer. MT-125 appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 2 original sources each.
Last mentioned: Mar 10, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Of the tracked stories, 1 of 1 also mention BioFlorida, the most common co-covered peer. MT-125 appears in 1 tracked Biotech story from March 10, 2026. The tracked stories average 2 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 19 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MT-125. Shared-story counts are live from our verified record — not editorial picks.
Clinical Milestones
Anticipated updates on Phase 1/2 trial progress for MT-125 in GBM.
BioFlorida Showcase
Presentation in the Cornerstone Session: Innovation at BioFlorida.
Investival Showcase
Participation in the South Florida - The Rising Life Science Hub event.
Conference Announcement
Invited to present at two major South Florida life sciences events.
Partnering Circuit
Presented at BioCom California Global Life Science Partnering Conference.
Myosin Therapeutics is set to present its first-in-class NMIIA/IIB inhibitor, MT-125, at two major South Florida life sciences conferences this March. The company's unique approach targets the physical mechanics of glioblastoma cells, offering a potential solution to traditional drug resistance.
MT-125 is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
